Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Eslava, Irosoki ^a   Payares, Gilberto ^a   Pernia, Beatriz M ^b   Holder, Anthony A ^c   Spencer, Lilian M ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b UNIVERSIDAD SIMÓN BOLÍVAR   (Venezuela)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONOCLONAL ANTIBODY; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BAGG ALBINO MOUSE; BLOODSTREAM INFECTION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; GIEMSA STAIN; HYBRIDOMA CELL CULTURE; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; INFECTION CONTROL; INOCULATION; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PASSIVE IMMUNIZATION; PLASMODIUM YOELII; SPLEEN; SURVIVAL; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; BLOOD; IMMUNOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; EPITOPES; MALARIA; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; PARASITEMIA; PLASMODIUM YOELII;

EID: 77949301892     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-46     Document Type: Article

References (23)

1. World Malaria Report 2008. World Health Organization, http://apps.who.int/malaria/wmr2008/
2. The precursor to major merozoite surface antigens: structure and role in immunity. AA Holder, Prog Allergy 1988 41 72 97
3. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. MJ Blackman IT Ling SC Nicholls AA Holder, Mol Biochem Parasitol 1991 49 29 33
4. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. AA Holder, Parasitology 2009 1 12
5. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia. LM Spencer Valero SA Ogun SL Fleck IT Ling TJ Scott-Finnigan MJ Blackman AA Holder, Infect Immun 1998 66 3925 3930
6. Immunization against malaria with a recombinant protein. IT Ling SA Ogun AA Holder, Parasite Immunol 1994 16 63 67
7. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. H Towbin T Staehelin J Gordon, Proc Natl Acad Sci USA 1979 76 4350 4354
8. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. TM Daly CA Long, Infect Immun 1993 61 2462 2467
9. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. C Hirunpetcharat JH Tian DC Kaslow N van Rooijen S Kumar JA Berzofsky LH Miller MF Good, J Immunol 1997 159 3400 3411
10. Passive immunization against murine malaria with an IgG3 monoclonal antibody. WR Majarian TM Daly WP Weidanz CA Long, J Immunol 1984 132 3131 3137
11. Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies. PA Benjamin IT Ling G Clottey LM Valero SA Ogun SL Fleck D Walliker WD Morgan B Birdsall J Feeney AA Holder, Mol Biochem Parasitol 1999 104 147 156
12. Antibodies and Plasmodium falciparum merozoites. R Ramasamy M Ramasamy S Yasawardena, Trends Parasitol 2001 17 194 197
13. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. MJ Blackman TJ Scott-Finnigan S Shai AA Holder, J Exp Med 1994 180 389 393
14. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. JA Guevara Patino AA Holder JS McBride MJ Blackman, J Exp Med 1997 186 1689 1699
15. The importance of human FcgammaRI in mediating protection to malaria. RS McIntosh J Shi RM Jennings JC Chappel TF de Koning-Ward T Smith J Green M van Egmond JH Leusen M Lazarou, et al. PLoS Pathog 2007 3 72
16. Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. RJ Pleass SA Ogun DH McGuinness JG van de Winkel AA Holder JM Woof, Blood 2003 102 4424 4430
17. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. HL Rotman TM Daly R Clynes CA Long, J Immunol 1998 161 1908 1912
18. Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors. P Vukovic PM Hogarth N Barnes DC Kaslow MF Good, Infect Immun 2000 68 3019 3022
19. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. R Yuan R Clynes J Oh JV Ravetch MD Scharff, J Exp Med 1998 187 641 648
20. Divergent roles for Fc receptors and complement in vivo. JV Ravetch RA Clynes, Annu Rev Immunol 1998 16 421 432 10.1146/annurev.immunol.16.1.421 9597136
21. Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. AL Gavin N Barnes HM Dijstelbloem PM Hogarth, J Immunol 1998 160 20 23 9551950
22. Parasite-specific immunoglobulin isotypes during lethal and non-lethal murine malaria infections. EC Smith AW Taylor-Robinson, Parasitol Res 2003 89 26 33
23. Opinion: Antibody-based therapies for malaria. RJ Pleass AA Holder, Nat Rev Microbiol 2005 3 893 899